CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
These initiatives signify a substantial boost to healthcare infrastructure across India, aligned with the Prime Minister’s mission of ensuring quality healthcare services nationwide
The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market
Union Government will provide a health cover of Rs. 5 lakh to any elderly person above 70 years of age
Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.
Revolf's infertility and miscarriage tests are a new technology that uses blood tests to detect neoself-antibodies
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
Silica is a proven and highly effective anti-caking agent that has been used for decades
Company receives acceptability, in principle, for ZyVac TCV making it eligible for purchase by United Nations procurement agencies
Subscribe To Our Newsletter & Stay Updated
